Cardiff Oncology (NasdaqCM:CRDF) Update / briefing March 25, 2026 04:30 PM ET Company ParticipantsHeinz-Josef Lenz - University Professor of Medicine, Preventive Medicine, and Cancer BiologyMani Mohindru - Interim CEOScott Kopetz - Professor and Deputy Chair in the Department of Gastrointestinal Medical OncologyConference Call ParticipantsMarc Frahm - Managing Director and Senior Research AnalystMaury Raycroft - Equity Research AnalystModeratorPlease be advised that today's conference is being recorded. I w ...

Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS Newswire / March 25, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported audited financial results for the year ended December 31, 2025, and provided a corporate update highlighting sign ...

Nautilus Biotechnology (NasdaqGS:NAUT) Conference March 25, 2026 01:00 PM ET Company ParticipantsAnna Mowry - CFOSujal Patel - Founder and CEOSujal PatelHello, everyone. I'm Sujal Patel, Founder and CEO of Nautilus Biotechnology, and I'm joined with by Anna Mowry, our Chief Financial Officer. We're here to talk about Nautilus unlocking the power of the proteome to revolutionize biomedicine. As we begin, this is our standard safe harbor statement. This presentation and my oral remarks have forward-looking st ...

Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026 Accessibility StatementSkip Navigation About Caris Life Sciences Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advance ...

Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data Accessibility StatementSkip Navigation Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced a new partnership with leading ...

"In precision oncology, treatment selection is not only about identifying what may work but also understanding factors that may affect how safely a patient can receive therapy," said Caris President David Spetzler, MS, PhD, MBA. "During Colorectal Cancer Awareness Month, it is important to recognize that DPYD testing can provide clinically meaningful information before treatment begins, helping clinicians make more informed decisions for patients who may be candidates for fluoropyrimidine-based therapy." As ...

Key Takeaways Markets often fall during wars but later recover as economies adjust and policy support is introduced.Defense, energy and commodities often perform better during conflicts due to spending and demand shifts.Gold, commodities and crypto can act as hedges or alternative assets during geopolitical uncertainty.Tempus AI (TEM) sits at the intersection of diagnostics, data and artificial intelligence. The company is building a precision medicine platform designed to help physicians, researchers and d ...

Core Insights - Trinity Biotech has announced the successful results of a clinical study for an enhanced version of its EpiCapture™ prostate cancer test, which utilizes machine learning for improved risk prediction of aggressive prostate cancer [1][6]. Group 1: Product Development and Clinical Validation - The next-generation EpiCapture™ test incorporates machine learning tools that consider additional patient features, including ethnicity, alongside DNA biomarkers, leading to more accurate risk prediction scores [2]. - The upgraded test was evaluated in a clinical study involving approximately 750 patient samples, providing a more ethnically diverse cohort than previous studies [5]. - The new version of the EpiCapture™ test achieved a clinical accuracy (Area Under the Curve, AUC) of 85%, indicating strong performance in oncology diagnostics [6]. Group 2: Market Context and Need - Prostate cancer is the most common non-skin cancer among men in the U.S., with about 1 in 8 men diagnosed during their lifetime, and national expenditures for prostate cancer care exceeding $20 billion annually [4]. - The EpiCapture test offers a less invasive and more accessible alternative to traditional diagnostic methods, addressing barriers to early detection such as the high costs and risks associated with MRI scans and needle biopsies [3]. Group 3: Commercialization Strategy - Trinity Biotech plans to commercialize the EpiCapture test as a proprietary Laboratory Developed Test (LDT) through its New York State Department of Health certified diagnostics reference laboratory, facilitating rapid rollout across the U.S. [8]. - This marks Trinity Biotech's first entry into the precision oncology diagnostics market, reflecting the company's strategic evolution towards precision medicine applications [9]. Group 4: Expert Commentary - John Gillard, CEO of Trinity Biotech, emphasized that the enhanced EpiCapture test represents significant progress in prostate cancer risk prediction and the company's innovation agenda [10]. - Dr. Antoinette Perry from University College Dublin highlighted the study's strong performance and the test's unique incorporation of ethnicity as a variable in its predictive algorithm, addressing the variations in prostate cancer incidence and outcomes across different populations [10].

Diamyd Medical enters into equity financing agreements with new U.S. sector specialist investors for up to USD 125 million and announces full enrollment in Phase 3 trial Accessibility StatementSkip Navigation NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLA ...

Company Overview - Cogent Biosciences is a biotechnology company focused on developing targeted therapies for genetically defined diseases, leveraging a focused R&D pipeline and strategic licensing partnerships to advance novel treatments for underserved patient populations [5] - The company has a market capitalization of $5.4 billion and a current stock price of $33.38, which has increased by 360% over the past year [4][6] - Cogent's lead candidate, CGT9486, targets systemic mastocytosis and gastrointestinal stromal tumors, with a business model centered on research, development, and licensing agreements [7] Investment Activity - RTW Investments disclosed a significant increase in its stake in Cogent Biosciences by acquiring 4,124,755 shares, valued at approximately $115.95 million [1][2] - Following this transaction, RTW's position in Cogent now represents 2.7% of its 13F reportable assets under management (AUM) [6] - The overall position value for Cogent increased by $219.88 million, reflecting both trading and market price changes [2] Financial Position - Cogent Biosciences ended the year with approximately $900 million on its balance sheet, providing sufficient runway into 2028 while advancing multiple regulatory filings for its lead drug [9] - The company is positioned to potentially validate years of R&D with upcoming FDA decisions, including an accepted application with a late-2026 decision timeline [9][10] Market Context - The investment in Cogent is seen as a conviction play, indicating a shift from promise to execution, with a focus on clinical success translating into commercial reality [8] - The stock's rapid ascent raises questions about whether upcoming approvals can justify its valuation and validate the extensive R&D efforts [10]